Atlas Trials

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

Clinical trial NCT03802630 · TERMINATED

Trial details

NCT number
NCT03802630
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Branch Retinal Vein Occlusion
Start date
2019-07-02
Primary completion
2021-07-26
Enrollment
450

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.